Anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy.
Anantharaman Giridhar, T Lekha, Kiran Chandran
https://pubmed.ncbi.nlm.nih.gov/42054086/Actively Recruiting
Led by Association for Innovation and Biomedical Research on Light and Image · Updated on 2026-02-06
120
Participants Needed
31
Research Sites
N/A
Total Duration
Researchers are evaluating the effectiveness, safety, and lasting effects of faricimab in Caucasian patients with symptomatic macular polypoidal choroidal vasculopathy PCV. PCV is a type of choroidal vasculopathy that causes hemorrhagic and exudative macular degeneration. This study aims to see how intravitreal injections of faricimab 6 mg affect best corrected visual acuity BCVA outcomes in these patients, addressing the current unmet needs due to disease heterogeneity and treatment challenges. The study involves administering faricimab injections directly into the eye following a treat and extend regimen tailored to each patient. It is an open-label, single-arm study lasting approximately 100 weeks, including a screening period of up to 28 days, a 12-week treatment initiation period, and a subsequent treat and extend phase extending to week 100. Participants receive faricimab at intervals up to 24 weeks based on their response and the study protocol. Participants will undergo regular eye examinations, safety assessments, and visual acuity testing using the ETDRS protocol. The study will monitor changes in BCVA from baseline through weeks 40, 44, 48, and up to 104 weeks, along with imaging to assess polypoidal lesion regression and retinal thickness. Adverse events will be tracked throughout the study. Overall participation spans more than two years, allowing detailed evaluation of faricimabs effects on vision and eye health in this population.
CONDITIONS
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
J
Joana F Tavares, PhD
L
Liliana C Soares, MsC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Association for Innovation and Biomedical Research on Light and Image
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 100 weeks
Participants receive faricimab 6 mg injections into the eye to treat symptomatic macular polypoidal choroidal vasculopathy, starting with an initiation period followed by a treat and extend regimen.
Multiple visits for treatment and assessments over approximately 100 weeks
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Anantharaman Giridhar, T Lekha, Kiran Chandran
https://pubmed.ncbi.nlm.nih.gov/42054086/Association for Innovation and Biomedical Research on Light and Image
Lead Sponsor